BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.6%

Neg 0% Neu 84.6% Pos 0%

BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $40 price target.

Comments

No comments yet. Be the first!